复方鹿花盘胶囊对乳腺增生小鼠子宫、卵巢重量影响及作用机制的研究

目的:观察复方鹿花盘胶囊对实验性乳腺增生小鼠子宫、卵巢及血清促卵泡雌激素(FSH)的影响。方法:采用苯甲酸雌二醇腹腔注射制造乳腺增生模型,观察复方鹿花盘胶囊对乳腺增生小鼠子宫、卵巢重量及重量指数的变化和对血清FSH含量的影响。结果:高剂量组能使乳腺增生小鼠子宫重量及其指数恢复接近正常,中、高剂量组均能升高FSH含量。结论:复方鹿花盘胶囊能不同程度的影响乳腺增生小鼠子宫、卵巢重量,其作用机理之一是调节FSH含量。

活血化瘀对血瘀证模型大鼠子宫 卵巢组织形态学的影响

目的:研究血瘀证模型大鼠的子宫、卵巢组织形态学变化,以及不同活血化瘀方药对血瘀证模型大鼠子宫、卵巢组织形态学的影响。方法:SD大鼠分为4组,每组10只,A、B组以生理盐水,C组以云南白药,D组以宫血停煎剂灌胃作预防性治疗。末次给药完成后B组(模型组),C、D组(治疗组)3组均造血瘀模型后,取子宫、卵巢切片HE染色观察,并取血进行血液流变学的检查。结果:血瘀证模型组(B组)与空白对照组(A组)比较,卵巢间质和增殖期子宫内膜出现明显血瘀证病理改变,而分泌期子宫内膜未见明显区别;血液流变学的各个方面均有极显著升高(P<0.01)。2治疗组(C、D组)与血瘀证模型组(B组)比较,卵巢间质和增生期子宫内膜、分泌期子宫内膜均未见明显血瘀证病理改变;血液流变学指标均有极显著降低(P<0.01)。结论:①运用肾上腺素+冰冻法制造的血瘀证模型,其增生期子宫内膜、卵巢具有较为明显的血瘀证病理改变,分泌期子宫内膜的改变则不明显。此种造模方法适合于妇科血瘀证的研究。②活血化瘀方药能够有效改善血瘀证模型的增殖期子宫内膜、卵巢的血瘀证病理改变。

女性生殖系统腺瘤样瘤误诊原因分析(附23例报告)

目的:探讨女性生殖系统腺瘤样瘤的发病部位、诊断、病理特点及误诊原因。方法:回顾性分析23例女性生殖系统腺瘤样瘤的病变部位、诊断方法、病理及免疫组织化学特点。结果:23例女性生殖系统腺瘤样瘤占子宫及卵巢肿瘤的0.82%,子宫与卵巢检出率分别为1.26%和0.25%,发病年龄27-52岁,平均年龄41岁,其中合并子宫平滑肌瘤17例,占74%,腺肌病6例,占26.1%。术前患者无特征性表现,确诊需依赖病理检查及免疫组织化学检查。结论:女性生殖系统腺瘤样瘤很少见,确诊依赖于病理检查及免疫组织化学检查,其生物学行为是良性。

Atypical Endometriosis:a Clinicopathologic Study of 163 Cases

OBJECTIVE To investigate the clinicopathologic features of atypical endometriosis （AEM）, and to discuss the relations between AEMs and tumors. METHODS A retrospective analysis was performed on 163 cases of AEMs. The changes in the glandular epithelium, stroma, and their background and the relationship with coexisting tumors were observed. RESULTS The AEMs account of for 4.4% （163/3,724） of the endometriosis （EM） cases. Of 172 AEM foci of 163 patients, 168 were in the ovary, and the other 4 were in the fallopian tube, cervix and uterine serosa. Of the cases of ovarian EM, 6.8% were AEM. All of the 27 cases （15.7%） of the AEMs associated with a tumor were found in the ovaries, of which 15 were malignant, 9 borderline, and 3 benign. Of the ovary AEMs, 14.9% were associated with a borderline or malignant tumor. The AEM epithelia were mainly arranged in the form of surface epithelia, with only a few glands. Present were characteristic features of moderate to marked pleomorphism, epithelial tufting, bud or firework-like structures on microscopy. Epithelial metaplastic changes were observed in 86 cases （50%） of the 172 AEM foci. Epithelium, endometrioid stroma, and fibrotic-collagen formed a three-layer structure in the wall of the AEM cysts. The endometrioid stroma were usually thin compared to the fibro-collagen tissue. The transformation from an AEM to a tumor was found in most of the malignant tumors. CONCLUSION AEM lesions have some features which are similar and also differ from both of the tumor and EM. AEMs have a relative higher potential for tumorigenesis and canceration, especially for ovarian cancer. The process of damage, repair, and scarring in EM foci over a long period may play a role in the development of EM into AEM and eventally into tumor formation.

OVEREXPRESSION OF p53, EGFR,C-ERBB2 AND C-ERBB3 IN ENDOMETRIOIDCARCINOMA OF THE OVARY

Objectives. To determine overexpression of p53, EGFR, c-erbB-2 and c-erbB-3 in endometrioid carcinoma of the ovary and to evaluate the prognostic significance of these results, especially, coexisting overexpression of p53 and one of the member of type I growth factor receptor family.Methods. Overexpressions of the p53, EGFR, c-erbB-2 and c-erbB-3 protein were studied by im-munohistochemistry in paraffin-embedded tumor tissue from 28 patients with endometrioid carcinoma of the ovary.Results. 11 (39.3%), 13 (46. 4%), and 14 (50. 0%) were stained positively with p53, c-erbB-2 and c-erbB-3 monoclonal antibodies. 13 (46- 4%) was stained positively with EGFR polyclonal antibody. There were no relationship between p53, EGFR, C-erbB-2, c-erbB-3 and histologic grade, lymph node metastasis. The percentage of tumors with over expression of p53, EGFR, C-erbB-2 and c-erbB-3 was higher in those with stage Ⅱ-Ⅲ tumors compared with those with stage Ⅰ , in patients with residual tumor after initial surgery compared with those without. A high survival rate was observed in patients without p53, EGFR, c-erbB-2 and c-erbB-3 overexpression respectively than those with. A highest survival rate was observed in patients with both p53 and one of EGFR, c-erbB-2 and c-erbB-3 negative compared with those both positive or either of both positive.Conclusion. Overexpression of p53, EGFR, c-erbB-2 and C-erbB-3 resulted in a poorer prognosis respectively. Overexpression of both p53 and one of the EGFR, c-erbB-2 and c-erbB-3 is a worse prognostic indicator in patients with endometrioid carcinoma of the ovary.

中医药治疗女性儿童性早熟的临床疗效观察研究

目的研究中医药治疗女性儿童性早熟的临床疗效,为女性儿童性早熟的临床治疗提供依据。方法选择该院在2014年1月至2019年12月门诊诊治的女性儿童性早熟患者60例,采用中医药疗法为患儿进行治疗,分析患儿治疗后的疗效,比较患儿治疗前后黄体生成激素、雌二醇和卵泡生成激素水平,子宫、卵巢三径改变、骨龄进展、乳房大小的改变。结果治疗前,患者黄体生成激素、雌二醇和卵泡生成激素水平比较,差异无统计学意义(P>0.05);治疗后,患者黄体生成素、雌二醇和卵泡雌激素水平较前改善或达到维持治疗前水平,子宫卵巢三径较治疗前缩小、骨龄无变化或骨龄进展符合生物时间推移,乳房缩小至青春期前水平B1期,比较差异有统计学意义(P<0.05)。结论采用中医药疗法为女性儿童性早熟患者进行治疗,可以有效提高疾病的临床治疗效果,并降低患者的雌激素水平,延缓骨龄进展,临床效果显著。